Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00837031 · ClinicalTrials.gov registry record · Phase 2
Lenalidomide With Gemcitabine in Treatment of Untreated Advanced Carcinoma of the Pancreas
A Phase 2 study, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
NCT00837031: Completed Phase 2 study, sponsored by SCRI Development Innovations.
NCT00837031 is a Phase 2 study that has completed, run by SCRI Development Innovations. The registered enrollment target is 72 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (46% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00837031, a Phase 2 study, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
Study Summary
To evaluate the 6-month overall survival, safety, and tolerability of lenalidomide in combination with standard gemcitabine as first-line treatment for patients with metastatic pancreatic cancer.
Primary Outcome
The percentage of patients who were alive 6 months after beginning treatment
Interventions
- DRUG Lenalidomide
- DRUG Gemcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2009-02 |
| Est. Completion | 2012-06 |
| Phase | Phase 2 |
What the finished NCT00837031 record still lists
NCT00837031 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (46% lower).
The record links to 0 conditions, and to 2 interventions - of which Lenalidomide is the first listed.
NCT00837031 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00837031 about?
NCT00837031 is a clinical study titled "Lenalidomide With Gemcitabine in Treatment of Untreated Advanced Carcinoma of the Pancreas". To evaluate the 6-month overall survival, safety, and tolerability of lenalidomide in combination with standard gemcitabine as first-line treatment for patients with metastatic pancreatic cancer.
What is the current status of trial NCT00837031?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2009-02. Estimated completion is 2012-06.
What interventions are being tested in trial NCT00837031?
The interventions under investigation include: Lenalidomide (DRUG), Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT00837031?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00837031's enrollment target sits among peer trials
72 925th of 2000 higher than 1,065 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia